{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:22:26Z","timestamp":1790713346738,"version":"4.1.0"},"reference-count":23,"publisher":"Walter de Gruyter GmbH","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,4,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_pp-2016-0017_s_012_w2aab3b7c19b1b6b1aab1c15b1Aa\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Peritoneal metastasis (PM) develop in more than 50\u2006% of gastric cancer (GC) patients. Median survival without treatment is not more than 3\u20137 months, and 8\u201312 months after modern combination chemotherapy. Innovative therapeutic approaches are urgently needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2016-0017_s_013_w2aab3b7c19b1b6b1aab1c15b2Aa\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Phase-2, open label prospective clinical trial assessing safety and efficacy of bidirectional chemotherapy for treating peritoneal metastasis of gastric cancer (PMGC). Treatment protocol included initial staging laparoscopy or laparotomy, 3\u20134 courses of systemic chemotherapy (XELOX) followed by Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) procedures every 6 weeks until progression of disease or death. Primary endpoints were overall survival and histological peritoneal regression grading score after rebiopsy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2016-0017_s_014_w2aab3b7c19b1b6b1aab1c15b3Aa\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>31 patients were included (9 men, 22 women, mean age 52 years), 24 with synchronous PM at diagnosis, 7 with metachronous PM after previous chemotherapy. Mean PCI was 13.8 (min-max 6\u201334). XELOX was administered in all patients and combined with 56 PIPAC procedures. Complete and partial pathological response was found in 60\u2006% of the 15 patients eligible for tumor response assessment (4 and 5 patients, respectively). Median survival was 13 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2016-0017_s_015_w2aab3b7c19b1b6b1aab1c15b4Aa\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Bidirectional chemotherapy combining XELOX with PIPAC with cisplatin and doxororubicin is well tolerated, can induce objective tumor regression and is associated with a promising survival in PMGC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/pp-2016-0017","type":"journal-article","created":{"date-parts":[[2016,9,19]],"date-time":"2016-09-19T08:05:37Z","timestamp":1474272337000},"page":"159-166","source":"Crossref","is-referenced-by-count":84,"title":["Bidirectional chemotherapy in gastric cancer with peritoneal metastasis combining intravenous XELOX with intraperitoneal chemotherapy with low-dose cisplatin and Doxorubicin administered as a pressurized aerosol: an open-label, Phase-2 study (PIPAC-GA2)"],"prefix":"10.1515","volume":"1","author":[{"given":"Vladimir","family":"Khomyakov","sequence":"first","affiliation":[{"name":"Moscow Research Oncological Institute n.a. P.A. Herzen , Thoracoabdominal, 2-nd Botkinsky proesd, 3 , Moscow 125284, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey","family":"Ryabov","sequence":"additional","affiliation":[{"name":"Moscow Research Oncological Institute n.a. P.A. Herzen, Thoracoabdominal , Moscow , Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey","family":"Ivanov","sequence":"additional","affiliation":[{"name":"Moscow Research Oncological Institute n.a. P.A. Herzen, Thoracoabdominal , Moscow , Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa","family":"Bolotina","sequence":"additional","affiliation":[{"name":"Moscow Research Oncological Institute n.a. P.A. Herzen , Chemotherapy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Utkina","sequence":"additional","affiliation":[{"name":"Moscow Research Oncological Institute n.a. P.A. Herzen, Thoracoabdominal , Moscow , Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadezhda","family":"Volchenko","sequence":"additional","affiliation":[{"name":"Moscow Research Oncological Institute n.a. P.A. Herzen , Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey","family":"Kaprin","sequence":"additional","affiliation":[{"name":"Moscow Research Oncological Institute n.a. P.A. Herzen , Director General"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2016,9,20]]},"reference":[{"key":"2025120909192063605_j_pp-2016-0017_ref_001_w2aab3b7c19b1b6b1ab2b1b1Aa","unstructured":"1. Kaprin A, Starinskii V, Petrova G. Current state of medical service for oncological diseases in Russia in 2014. 2016:62."},{"key":"2025120909192063605_j_pp-2016-0017_ref_002_w2aab3b7c19b1b6b1ab2b1b2Aa","doi-asserted-by":"crossref","unstructured":"2. Kaprin A, Sobolev D, Khomiakov V. Experience with hyperthermic intraoperative intraperitoneal chemotherapy in the treatment of locally advanced gastric cancer (Cyt+). Onkologiya Zhurnal imeni PA Gerzena 2015;1:67\u201370.","DOI":"10.17116\/onkolog20154167-70"},{"key":"2025120909192063605_j_pp-2016-0017_ref_003_w2aab3b7c19b1b6b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"3. Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 2008;359:453\u201362.","DOI":"10.1056\/NEJMoa0707035"},{"key":"2025120909192063605_j_pp-2016-0017_ref_004_w2aab3b7c19b1b6b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"4. Spolverato G, Ejaz A, Kim Y, Squires MH, Poultsides GA, Fields RC, et al. Rates and patterns of recurrence after curative intent resection for gastric cancer: a United States multi-institutional analysis. J Am Coll Surg 2014;219:664\u201375.","DOI":"10.1016\/j.jamcollsurg.2014.03.062"},{"key":"2025120909192063605_j_pp-2016-0017_ref_005_w2aab3b7c19b1b6b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"5. Roviello F, Marrelli D, de Manzoni G, Morgagni P, Di Leo A, Saragoni L, et al. Prospective study of peritoneal recurrence after curative surgery for gastric cancer. Br J Surg 2003;90:1113\u201319.","DOI":"10.1002\/bjs.4164"},{"key":"2025120909192063605_j_pp-2016-0017_ref_006_w2aab3b7c19b1b6b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"6. Thomassen I, van Gestel YR, van Ramshorst B, Luyer MD, Bosscha K, Nienhuijs SW, et al. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer 2014;134:622\u20138.","DOI":"10.1002\/ijc.28373"},{"key":"2025120909192063605_j_pp-2016-0017_ref_007_w2aab3b7c19b1b6b1ab2b1b7Aa","doi-asserted-by":"crossref","unstructured":"7. Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000;88:358\u201363.","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O"},{"key":"2025120909192063605_j_pp-2016-0017_ref_008_w2aab3b7c19b1b6b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"8. Kuramoto M, Shimada S, Ikeshima S, Matsuo A, Yagi Y, Matsuda M, et al. Extensive intraoperative peritoneal lavage as a standard prophylactic strategy for peritoneal recurrence in patients with gastric carcinoma. Ann Surg 2009;250:242\u20136.","DOI":"10.1097\/SLA.0b013e3181b0c80e"},{"key":"2025120909192063605_j_pp-2016-0017_ref_009_w2aab3b7c19b1b6b1ab2b1b9Aa","doi-asserted-by":"crossref","unstructured":"9. Mori T, Fujiwara Y, Sugita Y, Azama T, Ishii T, Taniguchi K, et al. Application of molecular diagnosis for detection of peritoneal micrometastasis and evaluation of preoperative chemotherapy in advanced gastric carcinoma. Ann Surg Oncol 2004;11:14\u201320.","DOI":"10.1007\/BF02524340"},{"key":"2025120909192063605_j_pp-2016-0017_ref_010_w2aab3b7c19b1b6b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"10. Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 2010;28:63\u20138.","DOI":"10.1200\/JCO.2009.23.9285"},{"key":"2025120909192063605_j_pp-2016-0017_ref_011_w2aab3b7c19b1b6b1ab2b1c11Aa","doi-asserted-by":"crossref","unstructured":"11. Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, et al. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer 2010;116:5608\u201318.","DOI":"10.1002\/cncr.25356"},{"key":"2025120909192063605_j_pp-2016-0017_ref_012_w2aab3b7c19b1b6b1ab2b1c12Aa","doi-asserted-by":"crossref","unstructured":"12. Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 2009;27:6237\u201342.","DOI":"10.1200\/JCO.2009.23.9640"},{"key":"2025120909192063605_j_pp-2016-0017_ref_013_w2aab3b7c19b1b6b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"13. Gill RS, Al-Adra DP, Nagendran J, Campbell S, Shi X, Haase E, et al. Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity. J Surg Oncol 2011;104:692\u20138.","DOI":"10.1002\/jso.22017"},{"key":"2025120909192063605_j_pp-2016-0017_ref_014_w2aab3b7c19b1b6b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"14. Solass W, Kerb R, Murdter T, Giger-Pabst U, Strumberg D, Tempfer C, et al. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol 2014;21:553\u20139.","DOI":"10.1245\/s10434-013-3213-1"},{"key":"2025120909192063605_j_pp-2016-0017_ref_015_w2aab3b7c19b1b6b1ab2b1c15Aa","doi-asserted-by":"crossref","unstructured":"15. Dakwar GR, Shariati M, Willaert W, Ceelen W, De Smedt SC, Remaut K. Nanomedicine-based intraperitoneal therapy for the treatment of peritoneal carcinomatosis - Mission possible? [Review). Adv Drug Deliv Rev 2016 Jul 13;pii: S0169-409X(16)30212-5. doi: 10.1016\/j.addr.2016.07.001. [Epub ahead of print].","DOI":"10.1016\/j.addr.2016.07.001"},{"key":"2025120909192063605_j_pp-2016-0017_ref_016_w2aab3b7c19b1b6b1ab2b1c16Aa","doi-asserted-by":"crossref","unstructured":"16. Nadiradze G, Giger-Pabst U, Zieren J, Strumberg D, Solass W, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with low-dose cisplatin and doxorubicin in gastric peritoneal metastasis. J Gastrointest Surg 2016;20:367\u201373.","DOI":"10.1007\/s11605-015-2995-9"},{"key":"2025120909192063605_j_pp-2016-0017_ref_017_w2aab3b7c19b1b6b1ab2b1c17Aa","doi-asserted-by":"crossref","unstructured":"17. ESMO Meeting 2016. Ann Oncol 2016;27;ii51. doi: 10.1093\/annonc\/mdw199.166.","DOI":"10.1093\/annonc\/mdw199.166"},{"key":"2025120909192063605_j_pp-2016-0017_ref_018_w2aab3b7c19b1b6b1ab2b1c18Aa","doi-asserted-by":"crossref","unstructured":"18. Solass W, Sempoux C, Carr NY, Detlefsen S, Bibau F. Peritoneal sampling procedures and histological assessment of therapeutic response: Proposal of the Peritoneal Regression Grading Score (PRGS. Pleura Peritoneum 2016;1:99\u2013107.","DOI":"10.1515\/pp-2016-0011"},{"key":"2025120909192063605_j_pp-2016-0017_ref_019_w2aab3b7c19b1b6b1ab2b1c19Aa","doi-asserted-by":"crossref","unstructured":"19. Abbasi SY, Taani HE, Saad A, Badheeb A, Addasi A. Advanced gastric cancer in Jordan from 2004 to 2008: a study of epidemiology and outcomes. Gastrointest Cancer Res 2011;4:122\u20137.","DOI":"10.4061\/2011\/152125"},{"key":"2025120909192063605_j_pp-2016-0017_ref_020_w2aab3b7c19b1b6b1ab2b1c20Aa","doi-asserted-by":"crossref","unstructured":"20. Robella M, Vaira M, De Simone M. Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat peritoneal carcinomatosis. World J Surg Oncol 2016 Apr;29:128.","DOI":"10.1186\/s12957-016-0892-7"},{"key":"2025120909192063605_j_pp-2016-0017_ref_021_w2aab3b7c19b1b6b1ab2b1c21Aa","doi-asserted-by":"crossref","unstructured":"21. Tempfer CB, Celik I, Solass W, Buerkle B, Pabst UG, Zieren J, et al. Activity of pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in women with recurrent, platinum-resistant ovarian cancer: preliminary clinical experience. Gynecol Oncol 2014;132:307\u201311.","DOI":"10.1016\/j.ygyno.2013.11.022"},{"key":"2025120909192063605_j_pp-2016-0017_ref_022_w2aab3b7c19b1b6b1ab2b1c22Aa","doi-asserted-by":"crossref","unstructured":"22. Kwee RM, Kwee TC. Modern imaging techniques for preoperative detection of distant metastases in gastric cancer [Review). World J Gastroenterol 2015 Oct 7;21:10502\u20139. doi: 10.3748\/wjg.v21.i37.10502.","DOI":"10.3748\/wjg.v21.i37.10502"},{"key":"2025120909192063605_j_pp-2016-0017_ref_023_w2aab3b7c19b1b6b1ab2b1c23Aa","unstructured":"23. Technology Brief. Health Policy Advisory Committee on Technology. Queensland, Australia. Pressurized IntraPeritoneal Aerosol Chemotherapy. July 2015. https:\/\/www.health.qld.gov.au\/healthpact\/docs\/br"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/pp\/1\/3\/article-p159.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2016-0017\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2016-0017\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T09:51:27Z","timestamp":1765273887000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2016-0017\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,1]]},"references-count":23,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,9,15]]},"published-print":{"date-parts":[[2019,4,24]]}},"alternative-id":["10.1515\/pp-2016-0017"],"URL":"https:\/\/doi.org\/10.1515\/pp-2016-0017","relation":{},"ISSN":["2364-768X","2364-7671"],"issn-type":[{"value":"2364-768X","type":"electronic"},{"value":"2364-7671","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9,1]]}}}